

January 26, 2026

PRIOR AUTHORIZATION UPDATE FOR MEDICAL REVIEW GUIDELINE

SUMMARY OF NOTIFICATION

On April 1, 2026, the criteria for glucagon like peptide-1 (GLP1) medications will be subject to new prior authorization criteria for Marketplace only, as per posted Medical Review Guidelines (MRGs):

- Bydureon (exenatide)
- Byetta (exenatide)
- Exenatide
- Liraglutide
- Mounjaro (tirzepatide)
- Ozempic (semaglutide)
- Rybelsus (semaglutide)
- Trulicity (dulaglutide)
- Victoza (liraglutide)

KEY DETAILS

Please find updated glucagon like peptide-1 (GLP1) Medical Review Guideline policy on our [Community Provider Website](#) under the “Prior Authorization Requests: Essential Information & Supporting Clinical Documentation” section.